ARTICLE | Financial News
ApoGen expands series A to $11M
August 31, 2018 6:13 PM UTC
Drug-resistant cancer company ApoGen Biotechnologies Inc. raised an additional $4 million on Aug. 23 from M Ventures and existing investors in its series A round, bringing the round's total to $11 million. M Ventures is the venture arm of Merck KGaA (Xetra:MRK).
Keno Gutierrez, an investment director at M Ventures, joined ApoGen’s board...
BCIQ Company Profiles
BCIQ Target Profiles
Apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B)